Jose-Carlos Gutierrez-RamosSenior Vice President of Synlogic Inc.
Dr. Gutierrez is Senior Vice President and head of the BioTherapeutics Research Group, which includes three Research Units (RUs), the global Pharmacokinetics, Dynamics and Metabolism - New Biological Entities (PDM-NBE) department, and the Global BioTherapeutic Technologies (GBT) department.
Prior to joining Pfizer, Dr. Gutierrez was SVP and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK. Dr. Gutierrez built the iiCEDD as a global group of "drug hunters" that included biologists, chemists, pharmacologists, protein scientists and clinicians who were responsible for the discovery of drugs in that space all the way to Phase IIa (POC).
Prior to GSK he served at AMGEN Mountain View as Site Head and CSO. Previous to the AMGEN acquisition of Avidia he was the SVP of R&D, where he led a significant effort of novel protein therapeutics for autoimmune disease. Before his AVIDIA appointment, he served as CSO of Peptimmune Inc. in Cambridge where he was responsible for the development of peptide based therapeutics for autoimmune disease, including MS and diabetes. Before Peptimmune, Dr. Gutierrez served as Vice President, Inflammation at Millennium Pharmaceuticals, where he built and led a group of more than 150 scientists.
Dr. Gutierrez was also a faculty member at the Genetics department of Harvard Medical School, where he led a research team at the Center for Blood Research. Before coming to the US, he was member of the Basel Institute for Immunology in Basel, Switzerland and a fellow at the Max-Plank for Immunbiologie in Freiburg, Germany. Dr. Gutierrez received his masters in Chemistry and his Ph.D. in Immunology from the Autonoma University of Madrid, Spain.